Alpa Laboratories Ltd vs Ambalal Sarabhai Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Alpa Laboratories Ltd is ₹ 66.11 as of 18 May 14:00 . The P/E Ratio of Alpa Laboratories Ltd changed from 10.5 on March 2021 to 11.2 on March 2025 . This represents a CAGR of 1.30% over 5 yearsThe P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 years The Market Cap of Alpa Laboratories Ltd changed from ₹ 76.06 crore on March 2021 to ₹ 219.07 crore on March 2025 . This represents a CAGR of 23.56% over 5 yearsThe Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 years The revenue of Alpa Laboratories Ltd for the Dec '25 is ₹ 29.96 crore as compare to the Sep '25 revenue of ₹ 29.32 crore. This represent the growth of 2.18% The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The ebitda of Alpa Laboratories Ltd for the Dec '25 is ₹ 2.42 crore as compare to the Sep '25 ebitda of ₹ 0.82 crore. This represent the growth of 195.12% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The net profit of Alpa Laboratories Ltd changed from ₹ 5.1 crore to ₹ 1.9 crore over 7 quarters. This represents a CAGR of -43.12% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21% The Dividend Payout of Alpa Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alpa Laboratories Ltd

M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company as 'Alpa Laboratories Private Limited' on March 18, 1988 for manufacture of pharmaceutical formulations.
In 1998, the Company was converted into a Public Limited with effect from September 3, 1998.
The facility has manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. In 1997, the Company initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh.
The Unit commenced commercial production in the year 1999 of all types of formulations viz.
Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams. The company has manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark 'Alpa' which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company.

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

FAQs for the comparison of Alpa Laboratories Ltd and Ambalal Sarabhai Enterprises Ltd

Which company has a larger market capitalization, Alpa Laboratories Ltd or Ambalal Sarabhai Enterprises Ltd?

Market cap of Alpa Laboratories Ltd is 147 Cr while Market cap of Ambalal Sarabhai Enterprises Ltd is 247 Cr

What are the key factors driving the stock performance of Alpa Laboratories Ltd and Ambalal Sarabhai Enterprises Ltd?

The stock performance of Alpa Laboratories Ltd and Ambalal Sarabhai Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alpa Laboratories Ltd and Ambalal Sarabhai Enterprises Ltd?

As of May 18, 2026, the Alpa Laboratories Ltd stock price is INR ₹70.14. On the other hand, Ambalal Sarabhai Enterprises Ltd stock price is INR ₹32.34.

How do dividend payouts of Alpa Laboratories Ltd and Ambalal Sarabhai Enterprises Ltd compare?

To compare the dividend payouts of Alpa Laboratories Ltd and Ambalal Sarabhai Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.